DMT1 (NRAMP2/DCT1) genetic variability and resistance to recombinant human erythropoietin therapy in chronic kidney disease patients under haemodialysis.
نویسندگان
چکیده
a Faculdade de Farmácia, Serviço de Bioquímica, b Instituto de Biologia Molecular e Celular, and c Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto , d Instituto de Ciências da Saúde, Universidade Católica Portuguesa, Porto , e Centro de Investigação de Ciências da Saúde da Universidade da Beira Interior, Covilhã , f Instituto de Farmacologia e Terapêutica Experimental, Universidade de Coimbra, Coimbra , g FMC, Dinefro – Diálises e Nefrologia, SA, Maia , h Uninefro – Sociedade Prestadora de Cuidados Médicos e de Diálise, SA, Guimarães , Portugal
منابع مشابه
Iron uptake and Nramp2/DMT1/DCT1 in human bronchial epithelial cells.
The capacity of natural resistance-associated macrophage protein-2 [Nramp2; also called divalent metal transporter-1 (DMT1) and divalent cation transporter-1 (DCT1)] to transport iron and its ubiquitous expression make it a likely candidate for transferrin-independent uptake of iron in peripheral tissues. We tested the hypothesis that non-transferrin-bound iron uptake by airway epithelial cells...
متن کاملPHARMA COKINETICS OF RECOMBINANT ERYTHROPOIETIN AND RED CELL METABOLISM IN HAEMODIALYSIS PATIENTS
The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...
متن کاملrhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits
Anemia is a common complication in hemodialysis (HD) patients, mainly due to the insuffi‐ cient production of erythropoietin (EPO) by the failing kidneys [1]. Anemia itself can worsens cardiac function, cognitive function, exercise capacity and quality of life, and it has been independently associated with increased mortality and progression of renal disease [2, 3]. A successful management of a...
متن کاملBand 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients
Our aim was to study changes in red blood cell (RBC) membrane band 3 profile, as a cumulative marker of RBC changes, in chronic kidney disease (CKD) patients under haemodialysis and recombinant human erythropoietin (rhEPO) therapy and its linkage with resistance to this therapy. We studied 63 CKD patients, 32 responders and 31 non-responders to rhEPO therapy, and 26 healthy individuals. We eval...
متن کاملSecondary haemochromatosis in a haemodialysis patient.
A 39-year-old woman with end-stage renal disease, which was maintained on haemodialysis, developed secondary haemochromatosis after receiving blood transfusions and intravenous iron supplementation without sufficient serum ferritin concentration monitoring. The patient received intravenous deferoxamine three times a week, combined with high-dose recombinant human erythropoietin therapy and haem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Acta haematologica
دوره 120 1 شماره
صفحات -
تاریخ انتشار 2008